# SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

> **NCT04797507** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 33 (estimated)

## Conditions studied

- SHR-1210
- Anlotinib
- Advanced Esophageal Squamous Cell Cancer

## Interventions

- **DRUG:** SHR-1210 plus Anlotinib

## Key facts

- **NCT ID:** NCT04797507
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03
- **Primary completion:** 2023-08
- **Final completion:** 2024-08
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2021-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797507, "SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04797507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*